$22 million for a breakthrough kidney disease treatment
An Australian medical breakthrough that could revolutionise the way kidney disease is treated, supporting millions of patients, will receive $22 million. Through the Federal Government’s Biomedical Translation Fund (BTF), fund managers Brandon Capital Partners will invest funding in Certa Therapeutics. The funding will help commercialise Certa’s cutting edge kidney disease treatment, providing Australian patients with…